7 Best IBS Alternatives in 2026
Last updated: 7/31/2026 · 7 alternatives
IBS (IBS) is one of the more recognized cryptocurrencies with a current Value Score of 60/100. But is IBS the best choice in its segment? We identified 7 alternatives operating in the same market segment — ranked by our fundamental Value Score, which combines 10 on-chain and market metrics. Each alternative is compared against the original so you can decide with full data.
Not Financial Advice
This page is an informational analysis, not investment advice. The CryptoValue Score is an algorithmically generated rating from public data — it does not replace professional advice. Cryptocurrencies are highly volatile; total loss is possible. Read full risk disclaimer →
How we pick alternatives
How we pick alternatives: (1) Same category as IBS — functionally comparable projects (Layer-1 vs Layer-1, DeFi vs DeFi, etc.). (2) Sorted by Value Score descending — coins with stronger fundamentals are prioritized. (3) Market cap is shown for context: smaller caps have higher percentage upside, larger caps offer more liquidity and established adoption.
Injective (INJ)
Rank #99 · $492.84M · $4.93
Why an alternative: Significantly stronger fundamentals (score 70 vs 60) — same use case, higher data quality.
Pepe (PEPE)
Rank #59 · $1.15B · $0.000003
Why an alternative: Larger, more established position (market cap $1.15B) — lower idiosyncratic risk, more liquidity.
Aave (AAVE)
Rank #50 · $1.54B · $99.97
Why an alternative: Larger, more established position (market cap $1.54B) — lower idiosyncratic risk, more liquidity.
NEAR Protocol (NEAR)
Rank #40 · $2.16B · $1.66
Why an alternative: Larger, more established position (market cap $2.16B) — lower idiosyncratic risk, more liquidity.
Dogecoin (DOGE)
Rank #11 · $10.88B · $0.07008
Why an alternative: Larger, more established position (market cap $10.88B) — lower idiosyncratic risk, more liquidity.
Polkadot (DOT)
Rank #57 · $1.30B · $0.768125
Why an alternative: Larger, more established position (market cap $1.30B) — lower idiosyncratic risk, more liquidity.
Cardano (ADA)
Rank #18 · $6.29B · $0.168572
Why an alternative: Larger, more established position (market cap $6.29B) — lower idiosyncratic risk, more liquidity.
Side-by-Side Comparison
| Coin | Score | Market Cap | Price | 30d |
|---|---|---|---|---|
| IBS(IBS) · original | 60 | $22.71M | $24.87 | -7.34% |
| Injective(INJ) | 70(+10) | $492.84M | $4.93 | +5.30% |
| Pepe(PEPE) | 69(+9) | $1.15B | $0.000003 | +17.60% |
| Aave(AAVE) | 69(+9) | $1.54B | $99.97 | +14.30% |
| NEAR Protocol(NEAR) | 68(+9) | $2.16B | $1.66 | -10.70% |
| Dogecoin(DOGE) | 68(+8) | $10.88B | $0.07008 | -3.10% |
| Polkadot(DOT) | 67(+8) | $1.30B | $0.768125 | -8.30% |
| Cardano(ADA) | 67(+7) | $6.29B | $0.168572 | +13.00% |
Bottom Line
Currently Injective has a better Value Score than IBS (70 vs 60) in the same use case. That doesn't automatically mean "buy instead of IBS" — liquidity, network effects, and personal risk tolerance matter. But for investors actively looking for alternatives, the top 3 coins on this list are the best starting point for your own research.
IBS in Market Context
Market Position
IBS (IBS) currently sits in the long-tail without a stable top-100 rank — higher upside but materially elevated risk, with a current market cap of $22.71 M. IBS falls into a specialized category with valuation drivers that differ from mainstream L1s and DeFi tokens.
Recent Price Action
Current price $24.87 is at 61% of ATH ($40.64) — typical mid-cycle range with room in both directions. Over the last 7 days, IBS has moved sideways at −0.16%; over 30 days it has dropped −7.3%.
Valuation Signals
At 59.9/100, IBS is in "Fair Value" territory — market and fundamentals are balanced; no clear buy or sell signal from valuation alone. Low dev activity (score 30/100) is a cluster risk — project stagnation elevates long-term delisting risk. The NVT ratio (75/100) shows healthy network activity relative to market cap.
Risk Profile
Specialized tokens carry use-case concentration risk: if the core thesis fails, pivoting is rarely viable. Strong tokenomics (85/100): bounded emission, decentralized distribution, and no activation cliffs on the horizon. Outside the top 100, exchange liquidity is thin and slippage on larger trades is non-trivial.
Frequently Asked Questions
What is the best alternative to IBS?
Based on our Value Score, Injective (INJ, score 70/100) is currently the highest-rated alternative in the crypto segment. "Best" depends on your requirements though — liquidity, smart contract functionality, energy efficiency, etc.
Why should I consider alternatives to IBS?
Three main reasons: (1) Diversification — concentration risk in a single crypto is dangerous. (2) Higher upside potential — smaller coins in the same segment can rise more in percentage terms if fundamentals are solid. (3) Different trade-offs — e.g. higher transaction speed, lower fees, or better decentralization. Caveat: smaller coins also carry more risk and lower liquidity.
Are these alternatives better than IBS?
"Better" is subjective. The list is sorted by Value Score — coins with stronger fundamentals at the top. But the score doesn't capture everything: network effects, brand recognition, regulatory clarity, and adoption speed are additional factors. Use the list as a starting point for deeper research, not as a final buy decision.
How were these alternatives selected?
We filter all coins in our database (1000+ coins) by the same category as IBS, exclude IBS itself, and sort by Value Score descending. The top 7 are listed here. The list auto-updates as scores change (hourly).